Italfarmaco partners with Iktos on Artificial Intelligence to speed drugdiscovery breakthroughs for patients
Combines AI to increase the potential of novel histone deacetylase (HDAC) inhibitors in the non-oncological field
Combines AI to increase the potential of novel histone deacetylase (HDAC) inhibitors in the non-oncological field
7 September marks World Duchenne Awareness Day (WDAD), a disease in which we as a company are particularly involved.
September 7th is World Duchenne Muscular Dystrophy Awareness Day, a disease that sees us, as a company, at the forefront of the search for a drug that can slow down its progression.
World Duchenne Awareness Day represents a great action of the global Duchenne Community to raise awareness for children and young adults living with Duchenne and Becker Muscular Dystrophy. This year the special theme that deserves more attention is “Duchenne and the brain”.
"Donnenmd" is a project promoted by the pediatric area of the NeMO Center in Rome, in collaboration with the Agostino Gemelli University Hospital Foundation IRCCS with the aim of providing training and information on some neuromuscular pathologies with childhood onset and to enhance the experiences of affected and caregivers women.
The “Journal of Medicinal Chemistry” publishes a paper on the identification of new and highly selective inhibitors of histone deacetylase 6 (HDAC6) by the Italfarmaco drug discovery team.
Italfarmaco is devoted to bring the light of hope into the world of Duchenne by committing to develop drugs to slow down the disease progression...
Pittsburgh, PA, November 9, 2018 - Therapeutic Research in Neuromuscular Disorders Solutions (TRiNDS), a specialty contract research organization, and Italfarmaco SpA, a privately held [...]